Clinical Trial Update: GVAX Plus Checkpoint Blockade in Neuroblastoma [Phase 1]

View source ↗

Summary

The Phase 1 trial of GVAX plus checkpoint blockade in neuroblastoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma
• Solid Tumor

Drugs mentioned

• GVAX

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Neuroblastoma, Pediatric Solid Tumor | Phase 1 | Status: TERMINATED